Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]
Titel:
Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]
Auteur:
Oh, Jonathan Barve, Minal Senzer, Neil Aaron, Phylicia Manning, Luisa Wallraven, Gladice Bognar, Ernest Stanbery, Laura Horvath, Staci Manley, Meghan Nemunaitis, John Walter, Adam Rocconi, Rodney P.